Sihuan Pharmaceutical Holdings Group (0460) AI Stock Analysis

• Market Cap: $10.08B
• Dividend Yield: 1.94%
• Average Volume (3M): 139.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -0.11%
• EPS Growth: -290.77%
• Country: HK
• Employees: 2,667
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 9,329,999,000
• 10 Day Avg. Volume: 81,310,400
• 30 Day Avg. Volume: 139,136,657
• PEG Ratio: 0.09
• Price to Book (P/B): 2.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -811.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: HK$1.00 ▼(-7.41%Downside)

Sihuan Pharmaceutical faces significant financial challenges, with declining revenue and net losses impacting its overall score. Technical analysis provides some positive signals, but the negative P/E ratio and liquidity concerns weigh heavily on the valuation. The lack of earnings call information limits insights into future guidance.

Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model

Company Description

Sihuan Pharmaceutical Holdings Group (0460) is a leading pharmaceutical company based in China, primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. The company operates in sectors including cardiovascular, central nervous system, metabolism, and anti-infective drugs. Sihuan's core products include a diverse range of patented and generic medicines, as well as active pharmaceutical ingredients (APIs) that cater to a broad spectrum of medical needs.

How the Company Makes Money

Sihuan Pharmaceutical Holdings Group generates revenue through the sale of its pharmaceutical products, which include both branded and generic drugs. Key revenue streams include hospital sales, distribution through pharmacies, and partnerships with other pharmaceutical companies for research and development. The company benefits from a strong presence in China’s healthcare sector, and it leverages strategic alliances and collaborations to expand its market reach and enhance its product offerings. Additionally, Sihuan invests in research and development to innovate and bring new drugs to market, thereby ensuring a steady flow of revenue from its diverse product portfolio.

Sihuan Pharmaceutical Holdings Group Financial Statement Overview

Summary

Sihuan Pharmaceutical's financial performance is under pressure, with declining revenue and consistent net losses. The balance sheet shows a stable asset base but declining equity, and cash flow analysis indicates potential liquidity issues.

Income Statement

Sihuan Pharmaceutical's income statement reflects significant challenges in recent years. The company experienced a substantial decline in revenue from 2021 to 2024, with revenue decreasing from approximately 3.04 billion to 1.90 billion. Gross profit margins have remained relatively stable, but consistent net losses have been reported, indicating profitability issues. The EBIT and EBITDA margins have turned negative, suggesting operational inefficiencies and a need for cost management improvements.

Balance Sheet

The balance sheet indicates a mixed financial position. The company's debt-to-equity ratio is low, which is positive, but stockholders' equity has decreased over time. The equity ratio remains adequate, reflecting a stable asset base. However, the decline in total assets and stockholders' equity raises concerns about long-term financial stability.

Cash Flow

Cash flow analysis shows significant volatility. The company's free cash flow has fluctuated, with recent years showing negative free cash flow, indicating potential liquidity issues. Operating cash flow has also been inconsistent, with the most recent period showing zero, highlighting challenges in generating cash from operations. These factors suggest a need for improved cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.90B	1.86B	2.18B	3.04B	2.46B
Gross Profit	1.24B	1.30B	1.49B	2.43B	1.91B
EBITDA	-208.66M	334.31M	-1.54B	931.69M	714.06M
Net Income	-216.66M	-54.02M	-1.95B	416.51M	473.38M
Balance Sheet
Total Assets	10.53B	11.54B	12.14B	14.50B	13.04B
Cash, Cash Equivalents and Short-Term Investments	3.63B	4.37B	4.79B	5.79B	4.94B
Total Debt	942.76M	1.26B	1.19B	1.08B	755.05M
Total Liabilities	5.58B	6.40B	6.50B	5.35B	3.10B
Stockholders Equity	4.37B	4.43B	4.74B	8.28B	9.19B
Cash Flow
Free Cash Flow	57.51M	-95.93M	-355.97M	64.28M	-279.51M
Operating Cash Flow	243.89M	199.49M	46.49M	665.29M	227.13M
Investing Cash Flow	758.24M	169.88M	-1.66B	-337.57M	-924.78M
Financing Cash Flow	-1.26B	-419.56M	-238.93M	750.66M	184.54M

Sihuan Pharmaceutical Holdings Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Neutral. The current price of 1.08 is below the 20-day moving average (MA) of 1.12, above the 50-day MA of 0.93, and above the 200-day MA of 0.71, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 53.62 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0460.

Sihuan Pharmaceutical Holdings Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1681	82 Outperform	€9.21B	9.20	23.28%	5.42%	12.70%	9.91%
0719	70 Outperform	HK$10.16B	10.24	8.89%	3.84%	4.91%	-11.80%
1558	67 Neutral	HK$12.76B	24.41	5.88%	―	-42.02%	-76.29%
0570	58 Neutral	HK$11.08B	189.66	0.25%	0.14%	-10.72%	-95.88%
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
0460	50 Neutral	$10.08B	―	-4.93%	1.94%	-0.11%	-290.77%
6185	48 Neutral	HK$10.79B	―	-4.41%	―	94.98%	85.69%

Sihuan Pharmaceutical Holdings Group Corporate Events

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan Amidst Strong Product Launches

Sihuan Pharmaceutical Holdings Group Ltd. has announced a share repurchase plan of up to HK$500 million, with a recent repurchase of 20 million shares at an average price of HK$1.0910 per share. This move is part of the company’s strategy to enhance shareholder value and reflects confidence in its growth prospects. The company has made significant strides in its medical aesthetics and innovative pharmaceuticals sectors, with substantial revenue growth and the launch of numerous new products. This expansion is expected to drive future revenue and profit growth, reinforcing Sihuan Pharmaceutical’s position in the industry.

Sihuan Pharmaceutical’s New Breast Cancer Treatment Gains Regulatory Acceptance

Sihuan Pharmaceutical Holdings Group announced that their New Drug Application for a new indication of Bireociclib Tablets, in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer, has been accepted by China’s National Medical Products Administration. This development highlights the company’s strong R&D capabilities and positions them to provide comprehensive treatment options for breast cancer patients, addressing a significant demand in the global market for CDK4/6 inhibitors, which is projected to grow substantially.

Sihuan Pharmaceutical Approves Key Resolutions at AGM

Sihuan Pharmaceutical Holdings Group Ltd. held its Annual General Meeting on June 6, 2025, where all proposed resolutions were passed by shareholder vote. Key resolutions included the re-election of directors, re-appointment of Ernst & Young as auditors, and authorization for the board to manage share issuance and repurchase. These decisions reflect the company’s stable governance structure and strategic focus on maintaining financial and operational flexibility, potentially impacting its market positioning positively.

Sihuan Pharmaceutical’s Bireociclib Tablets Gain Approval for Advanced Breast Cancer Treatment

Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has received marketing authorization from the National Medical Products Administration for its innovative drug, Bireociclib Tablets, for two indications in HR+/HER2- advanced breast cancer. This approval marks a significant milestone as Bireociclib is the only CDK4/6 inhibitor approved in China for monotherapy in later-line treatment, showcasing the company’s strong R&D capabilities. The drug’s approval is expected to address treatment bottlenecks in breast cancer therapy, offering a promising solution for patients with limited options.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Strong Business Growth

Sihuan Pharmaceutical Holdings Group announced a share repurchase plan of up to HK$500 million, with the recent repurchase of 10 million shares at an average price of HK$0.6888 per share. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth. Sihuan has made significant progress in its medical aesthetics and pharmaceuticals segments, with substantial revenue growth and new product approvals. The company anticipates these developments will positively impact its revenue and profit, reinforcing its position in the industry.

Sihuan Pharmaceutical Announces Strategic Share Repurchase and Business Growth

Sihuan Pharmaceutical Holdings Group announced a share repurchase plan, buying back 20 million shares at an average price of HK$0.7342 per share, reflecting a strategic move to enhance shareholder value. The company has shown significant progress in its medical aesthetics and innovative pharmaceuticals sectors, with a notable revenue increase in its medical aesthetics business and the approval of 28 new products, which are expected to positively impact future revenue and profit.

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan

Sihuan Pharmaceutical Holdings Group Ltd. has announced a share repurchase plan of up to HK$500 million, reflecting its confidence in the company’s future prospects and commitment to enhancing shareholder value. This move aligns with its strategic goals, as the company continues to expand its medical aesthetics and biopharmaceutical businesses, with significant growth reported in its medical aesthetics segment and several new product approvals expected to boost revenue.

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan

Sihuan Pharmaceutical Holdings Group Ltd. announced a voluntary share repurchase plan, aiming to buy back shares worth up to HK$500 million, subject to market conditions. This move reflects the company’s confidence in its strategic direction and is expected to positively impact its financial performance. The company has made significant strides in its medical aesthetics and innovative pharmaceuticals segments, with a notable increase in revenue and several products reaching critical development milestones. These advancements are anticipated to enhance Sihuan’s market position and contribute to its future growth.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Business Growth

Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase plan, buying back 16,174,000 shares at an average price of HK$0.6731 per share, totaling approximately HK$10.89 million. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth. The company has seen significant progress in its medical aesthetics and innovative pharmaceuticals businesses, with a notable increase in revenue and the approval of new products. These developments are expected to positively impact the company’s revenue and profit, strengthening its position in the industry.

Sihuan Pharmaceutical Announces 2025 Annual General Meeting

Sihuan Pharmaceutical Holdings Group Ltd. has announced its annual general meeting scheduled for June 6, 2025, in Beijing, China. The meeting will cover the adoption of the company’s financial statements for 2024, re-election of directors, re-appointment of auditors, and resolutions regarding the issuance of additional shares. These resolutions, if passed, could influence the company’s financial strategies and shareholder value.

Sihuan Pharmaceutical’s Breakthrough in Regenerative Aesthetics with PLLA Filler Approval

Sihuan Pharmaceutical Holdings Group has achieved a significant milestone with its subsidiary, Meiyan Space, obtaining Class III medical device registration approval from China’s National Medical Products Administration for its Poly-L-lactic Acid Facial Filler (PLLA filler). This development strengthens Sihuan’s position in the regenerative medical aesthetic market, highlighting its technological leadership and competitive advantage. The approval is expected to drive the company’s growth in the medical aesthetic segment, supported by the rapidly expanding market for regenerative biomaterials in China.

Sihuan Pharmaceutical’s Dapagliflozin Tablets Gain Approval, Boosting Diabetes Treatment Portfolio

Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, received approval from China’s National Medical Products Administration for its Dapagliflozin Tablets, a treatment for type 2 diabetes. This approval enhances the company’s product lineup in the diabetes sector and provides improved treatment options for patients, aligning with the growing market demand for SGLT-2 inhibitors, which are recognized for their efficacy in managing blood glucose and offering cardiovascular and renal benefits.

Sihuan Pharmaceutical Announces Strategic Share Repurchase Plan

Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase plan of up to HK$500 million, with a recent repurchase of 10 million shares at an average price of HK$0.6274 per share. This move is part of the company’s strategic goal to strengthen its market position in medical aesthetics and biopharmaceuticals, with significant growth reported in its medical aesthetics segment and ongoing development of innovative drugs. The company expects these developments to positively impact its revenue and profit, reinforcing its confidence in future growth.

Sihuan Pharmaceutical’s Breakthrough in Breast Cancer Treatment

Sihuan Pharmaceutical Holdings Group Ltd. announced significant results from a phase 3 clinical trial of its innovative drug Bireociclib, in combination with Fulvestrant, for treating HR+/HER2- advanced breast cancer. The study, published in Nature Communications, demonstrated that the combination therapy significantly improved progression-free survival compared to Fulvestrant alone, marking a notable advancement in treatment options for complex and refractory breast cancer cases. This achievement underscores Sihuan Pharmaceutical’s strong R&D capabilities and commitment to addressing unmet clinical needs, enhancing its position in the pharmaceutical industry.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Strong Business Growth

Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase plan, buying back 10 million shares at an average price of HK$0.5866 per share, totaling approximately HK$5.87 million. This initiative is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth prospects. Sihuan Pharmaceutical has made significant strides in its medical aesthetics and innovative pharmaceuticals sectors, with substantial revenue growth and new product approvals, positioning itself as a leader in the Chinese market.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Strong Business Growth

Sihuan Pharmaceutical Holdings Group Ltd. announced a voluntary share repurchase plan, buying back 15 million shares at an average price of HK$0.5836 per share, totaling approximately HK$8.75 million. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in its future growth, driven by significant advancements in its medical aesthetics and innovative pharmaceuticals segments. The company reported a 65.4% year-on-year increase in revenue from its medical aesthetics business, and it has received approval for 21 new drugs in 2024, which are expected to boost future revenue and profit.